Switch to:
Also traded in: Denmark, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 59161.39
GNMSF's Cash to Debt is ranked higher than
100% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. GNMSF: 59161.39 )
Ranked among companies with meaningful Cash to Debt only.
GNMSF' s Cash to Debt Range Over the Past 10 Years
Min: 10.54  Med: 626.55 Max: 59161.39
Current: 59161.39
10.54
59161.39
Equity to Asset 0.90
GNMSF's Equity to Asset is ranked higher than
85% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GNMSF: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
GNMSF' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.45 Max: 0.9
Current: 0.9
0.21
0.9
Interest Coverage 11.10
GNMSF's Interest Coverage is ranked lower than
79% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 11.10 )
Ranked among companies with meaningful Interest Coverage only.
GNMSF' s Interest Coverage Range Over the Past 10 Years
Min: 17.98  Med: 8094.33 Max: 9999.99
Current: 11.1
17.98
9999.99
F-Score: 6
Z-Score: 101.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 47.96
GNMSF's Operating margin (%) is ranked higher than
96% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. GNMSF: 47.96 )
Ranked among companies with meaningful Operating margin (%) only.
GNMSF' s Operating margin (%) Range Over the Past 10 Years
Min: -348.38  Med: -49.34 Max: 64.46
Current: 47.96
-348.38
64.46
Net-margin (%) 44.69
GNMSF's Net-margin (%) is ranked higher than
96% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. GNMSF: 44.69 )
Ranked among companies with meaningful Net-margin (%) only.
GNMSF' s Net-margin (%) Range Over the Past 10 Years
Min: -323.31  Med: -86.46 Max: 67.39
Current: 44.69
-323.31
67.39
ROE (%) 17.35
GNMSF's ROE (%) is ranked higher than
92% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. GNMSF: 17.35 )
Ranked among companies with meaningful ROE (%) only.
GNMSF' s ROE (%) Range Over the Past 10 Years
Min: -112.03  Med: -29.60 Max: 27.67
Current: 17.35
-112.03
27.67
ROA (%) 15.04
GNMSF's ROA (%) is ranked higher than
94% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. GNMSF: 15.04 )
Ranked among companies with meaningful ROA (%) only.
GNMSF' s ROA (%) Range Over the Past 10 Years
Min: -36.89  Med: -20.21 Max: 22.56
Current: 15.04
-36.89
22.56
ROC (Joel Greenblatt) (%) 2167.68
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. GNMSF: 2167.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMSF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -451.72  Med: -43.92 Max: 2780.55
Current: 2167.68
-451.72
2780.55
Revenue Growth (3Y)(%) 21.00
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
75% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. GNMSF: 21.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMSF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.20 Max: 326.7
Current: 21
0
326.7
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MDVN, NAS:GRFS, NAS:JAZZ, NAS:BMRN, NAS:ALKS, OTCPK:NVZMY, OTCPK:UCBJF, NAS:DYAX, NAS:INCY, NAS:SGEN, NAS:OPK, OTCPK:SBMFF, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JUNO, NAS:TECH, OTCPK:ALIOY, OTCPK:BTGGF, NAS:ACAD » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S is an antibody company focused on cancer. Its first marketed product is Arzerra (ofatumumab); development pipeline incl. daratumumab and two proprietary technology platforms; DuoBody (bispecifics) & HexaBody (effector function enhancement).

Genmab A/S is a biotechnology company that utilizes antibody products. The Company's treatments focus on cancer and other serious illnesses. The Company has a pipeline of drugs in various stages of development and approval. The Company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The Company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The Company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The Company has a myriad of other products in development, pending completion and approval. The Company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.

Ratios

vs
industry
vs
history
P/E(ttm) 144.57
GNMSF's P/E(ttm) is ranked lower than
85% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. GNMSF: 144.57 )
Ranked among companies with meaningful P/E(ttm) only.
GNMSF' s P/E(ttm) Range Over the Past 10 Years
Min: 42.72  Med: 84.05 Max: 144.57
Current: 144.57
42.72
144.57
PE(NRI) 144.57
GNMSF's PE(NRI) is ranked lower than
86% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. GNMSF: 144.57 )
Ranked among companies with meaningful PE(NRI) only.
GNMSF' s PE(NRI) Range Over the Past 10 Years
Min: 42.64  Med: 84.05 Max: 181.04
Current: 144.57
42.64
181.04
Price/Owner Earnings (ttm) 495.36
GNMSF's Price/Owner Earnings (ttm) is ranked lower than
93% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 32.22 vs. GNMSF: 495.36 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GNMSF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 216.55  Med: 357.27 Max: 679.38
Current: 495.36
216.55
679.38
P/B 21.64
GNMSF's P/B is ranked lower than
93% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. GNMSF: 21.64 )
Ranked among companies with meaningful P/B only.
GNMSF' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 7.51 Max: 25.04
Current: 21.64
1.63
25.04
P/S 63.72
GNMSF's P/S is ranked lower than
77% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. GNMSF: 63.72 )
Ranked among companies with meaningful P/S only.
GNMSF' s P/S Range Over the Past 10 Years
Min: 3.08  Med: 13.88 Max: 66.78
Current: 63.72
3.08
66.78
PFCF 326.73
GNMSF's PFCF is ranked lower than
94% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 26.08 vs. GNMSF: 326.73 )
Ranked among companies with meaningful PFCF only.
GNMSF' s PFCF Range Over the Past 10 Years
Min: 3.76  Med: 69.14 Max: 7364.2
Current: 326.73
3.76
7364.2
POCF 214.41
GNMSF's POCF is ranked lower than
95% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 22.99 vs. GNMSF: 214.41 )
Ranked among companies with meaningful POCF only.
GNMSF' s POCF Range Over the Past 10 Years
Min: 3.66  Med: 123.35 Max: 1654.96
Current: 214.41
3.66
1654.96
EV-to-EBIT 123.88
GNMSF's EV-to-EBIT is ranked lower than
90% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. GNMSF: 123.88 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -390.4  Med: -0.50 Max: 1407.3
Current: 123.88
-390.4
1407.3
EV-to-EBITDA 123.88
GNMSF's EV-to-EBITDA is ranked lower than
91% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. GNMSF: 123.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNMSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1007.1  Med: -0.60 Max: 1407.3
Current: 123.88
-1007.1
1407.3
Current Ratio 9.48
GNMSF's Current Ratio is ranked higher than
75% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GNMSF: 9.48 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.88 Max: 9.48
Current: 9.48
1.3
9.48
Quick Ratio 9.48
GNMSF's Quick Ratio is ranked higher than
75% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. GNMSF: 9.48 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.88 Max: 9.48
Current: 9.48
1.3
9.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.76
GNMSF's Price/Net Cash is ranked lower than
85% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. GNMSF: 21.76 )
Ranked among companies with meaningful Price/Net Cash only.
GNMSF' s Price/Net Cash Range Over the Past 10 Years
Min: 7.38  Med: 13.99 Max: 75.2
Current: 21.76
7.38
75.2
Price/Net Current Asset Value 20.49
GNMSF's Price/Net Current Asset Value is ranked lower than
86% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. GNMSF: 20.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNMSF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.72  Med: 7.73 Max: 24.04
Current: 20.49
1.72
24.04
Price/Tangible Book 20.23
GNMSF's Price/Tangible Book is ranked lower than
91% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. GNMSF: 20.23 )
Ranked among companies with meaningful Price/Tangible Book only.
GNMSF' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 7.57 Max: 22.66
Current: 20.23
1.62
22.66
Price/Projected FCF 21.36
GNMSF's Price/Projected FCF is ranked lower than
85% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. GNMSF: 21.36 )
Ranked among companies with meaningful Price/Projected FCF only.
GNMSF' s Price/Projected FCF Range Over the Past 10 Years
Min: 17.14  Med: 32.01 Max: 407.96
Current: 21.36
17.14
407.96
Price/Median PS Value 4.07
GNMSF's Price/Median PS Value is ranked lower than
92% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. GNMSF: 4.07 )
Ranked among companies with meaningful Price/Median PS Value only.
GNMSF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.07 Max: 3.48
Current: 4.07
0.26
3.48
Price/Graham Number 10.73
GNMSF's Price/Graham Number is ranked lower than
94% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. GNMSF: 10.73 )
Ranked among companies with meaningful Price/Graham Number only.
GNMSF' s Price/Graham Number Range Over the Past 10 Years
Min: 4.02  Med: 6.46 Max: 10.79
Current: 10.73
4.02
10.79
Earnings Yield (Greenblatt) (%) 0.77
GNMSF's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. GNMSF: 0.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMSF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.30 Max: 325.7
Current: 0.77
0.1
325.7

More Statistics

Revenue (TTM) (Mil) $177.2
EPS (TTM) $ 1.30
Beta0.63
Short Percentage of Float0.00%
52-Week Range $83.99 - 183.00
Shares Outstanding (Mil)59.68
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion Jun 24 2016
Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as... Jun 23 2016
Market Selloff Hits Genmab While Buy Ratings Signal 20% Rebound Jun 13 2016
Market Rout Hits Genmab While Buy Ratings Signal 20% Rebound Jun 13 2016
These Are the Most Promising Experimental Cancer Drugs Jun 09 2016
Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis Jun 02 2016
Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen May 30 2016
Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for... May 23 2016
Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or... May 18 2016
Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for... May 17 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Genmab Announces Financial Results for the First Quarter of 2016 May 10 2016
Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting Apr 20 2016
Genmab Updates Financial Guidance for 2016 Apr 20 2016
Genmab A/S: Leads amongst peers with strong fundamentals Apr 08 2016
Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding... Apr 04 2016
CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory... Apr 01 2016
Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or... Mar 30 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : March 1, 2016 Mar 01 2016
Genmab A/S Earnings Analysis: 2015 By the Numbers Feb 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)